Dr. Reddy's Laboratories Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Erez Israeli

İcra Kurulu Başkanı

₹230.3m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	8.2yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Erez Israeli'un ücretlendirmesi Dr. Reddy's Laboratories'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	₹230m	n/a	₹43b
Dec 31 2025	n/a	n/a	₹57b
Sep 30 2025	n/a	n/a	₹59b
Jun 30 2025	n/a	n/a	₹57b
Mar 31 2025	₹175m	n/a	₹57b
Dec 31 2024	n/a	n/a	₹54b
Sep 30 2024	n/a	n/a	₹53b
Jun 30 2024	n/a	n/a	₹56b
Mar 31 2024	₹197m	n/a	₹56b
Dec 31 2023	n/a	n/a	₹52b
Sep 30 2023	n/a	n/a	₹51b
Jun 30 2023	n/a	n/a	₹47b
Mar 31 2023	₹195m	n/a	₹45b
Dec 31 2022	n/a	n/a	₹36b
Sep 30 2022	n/a	n/a	₹31b
Jun 30 2022	n/a	n/a	₹30b
Mar 31 2022	₹127m	n/a	₹24b
Dec 31 2021	n/a	n/a	₹26b
Sep 30 2021	n/a	n/a	₹19b
Jun 30 2021	n/a	n/a	₹17b
Mar 31 2021	₹120m	n/a	₹17b
Dec 31 2020	n/a	n/a	₹21b
Sep 30 2020	n/a	n/a	₹15b
Jun 30 2020	n/a	n/a	₹19b
Mar 31 2020	₹195m	₹107m	₹19b

Tazminat ve Piyasa: Erez 'nin toplam tazminatı ($USD 2.43M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.50M ).

Tazminat ve Kazançlar: Erez şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Erez Israeli (58 yo)

8.2yrs

Görev süresi

₹230,330,000

Tazminat

Mr. Erez Israeli, MBA has been Chief Executive Officer of Dr. Reddy's Laboratories Limited since August 1, 2019 and has been its Member of the Management Council since April 02, 2018. Mr. Israeli served as...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gunupati Prasad	Co-Chairman	40.2yrs	₹158.17m	13.07% € 1.3b
Kallam Reddy	Chairman of the Board & Member of the Management Council	33.4yrs	₹100.66m	13.61% € 1.3b
Erez Israeli	CEO & Member of the Management Council	8.2yrs	₹230.33m	Veri yok
Mannam Venkatanarasimham	CFO & Member of the Management Council	1.8yrs	₹72.48m	0.0074% € 713.0k
Krishna Venkatesh	Global Head of IPDO	2.4yrs	₹41.18m	Veri yok
Deepak Sapra	Global Head of Pharmaceutical Services and Active Ingredients & Member of Management Council	no data	₹50.89m	0.0091% € 879.6k
Motupalli Ramana	CEO of Global Generics & Member of Management Council	no data	₹89.25m	0.0082% € 793.4k
Sanjay Sharma	Executive VP	8.8yrs	₹71.07m	Veri yok
Patrick Aghanian	Head of Consumer Health Organization & Member of Management Council	no data	₹107.54m	Veri yok
Bhethanabottla Phanimitra	Chief Digital & Information Officer and Member of the Management Council	2.8yrs	₹37.54m	0.0010% € 101.7k
Milan Kalawadia	CEO of North America & Member of Management Council	2.1yrs	₹86.78m	0.0057% € 550.2k
M S Sundar	Global Head of Quality and PV & Member of Management Council	less than a year	Veri yok	0.0043% € 414.6k

2.4yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: RDDA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gunupati Prasad	Co-Chairman	40.2yrs	₹158.17m	13.07% € 1.3b
Kallam Reddy	Chairman of the Board & Member of the Management Council	33.4yrs	₹100.66m	13.61% € 1.3b
Claudio Albrecht	Independent Director	3.1yrs	₹20.24m	Veri yok
Arun Kumar	Independent Director	3.8yrs	₹22.14m	Veri yok
Shikha Sharma	Independent Director	7.4yrs	₹16.45m	Veri yok
Leo Puri	Lead Independent Director	7.7yrs	₹22.62m	Veri yok
Kodumudi Krishnan	Independent Director	4.4yrs	₹14.18m	Veri yok
Sanjiv Mehta	Independent Director	2.5yrs	₹17.40m	Veri yok
Alpna Seth	Independent Director	3.4yrs	₹19.77m	Veri yok
Penny Wan	Independent Director	4.4yrs	₹20.72m	Veri yok

4.4yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RDDA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/17 18:53
Gün Sonu Hisse Fiyatı	2026/06/17 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2026/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Dr. Reddy's Laboratories Limited 69 Bu analistlerden 37, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Rohit Bhat	360 ONE Capital Market Private Limited
Gaurav Tinani	Ambit Capital
null null	Anand Rathi Shares and Stock Brokers Limited

Dr. Reddy's Laboratories Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 24, 2025

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Recent updates

Dr. Reddy's Laboratories Limited to Report Q1, 2027 Results on Jul 22, 2026

Dr. Reddy’s Laboratories Announces First-To-Market Launch Of Bosutinib Tablets 400Mg, A Generic Equivalent Of Bosulif, In The United States

Dr. Reddy’S Laboratories Ltd. Launches Generic Semaglutide Injection in Canada

Dr. Reddy's Laboratories Limited announces Annual dividend, payable on August 22, 2026

Dr Reddys Laboratories Ltd Receives Health Canada Approval For Generic Semaglutide Injection

Enspirit Technology Services Private Limited entered into an agreement to acquire Svaas Wellness Limited from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 22.3 million.

CORONA Remedies Limited (NSEI:CORONA) acquired Wokadine Brand from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Limited to Report Q4, 2026 Results on May 12, 2026

Dr. Reddy's Announces USFDA Acceptance to Review its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Dr. Reddy's Laboratories Ltd. Announces the Launch of Over-The-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%

Dr. Reddy's Laboratories Limited to Report Q3, 2026 Results on Jan 21, 2026

USFDA Inspection Closes with Voluntary Action Indicated Classification

Eisai Co., Ltd. Announces Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for AVT03 (denosumab), A Proposed Biosimilar of Prolia®? and Xgeva®?

Dr. Reddy's Laboratories Limited to Report Q2, 2026 Results on Oct 24, 2025

Extrovis AG and Dr. Reddy's Announce the Launch of the Authorized Generic of Carac (Fluorouracil Cream), 0.5% in the U.S

Dr. Reddy's Laboratories Limited to Report Q1, 2026 Results on Jul 23, 2025

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 24, 2025

Dr. Reddy's Laboratories Limited Recommends A Final Dividend for the Financial Year 2024-25

Dr. Reddy's Laboratories Limited to Report Q4, 2025 Results on May 09, 2025

Dr. Reddy's Issues Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 Mg/100 mL, in the U.S., Due to Mislabeling of Infusion Bag

Senores Pharmaceuticals, Inc. agreed to acquire basket of 14 Abbreviated New Drug Applications from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Limited Provides Lawsuit Updates

Dr. Reddy's Laboratories Limited to Report Q3, 2025 Results on Jan 23, 2025

Dr. Reddy's Laboratories Ltd. Launches Toripalimab in India

Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Limited Complaint Made Public in the United States District Court for the District of New Jersey

Dr. Reddy's Laboratories Limited to Report Q2, 2025 Results on Nov 05, 2024

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Fiscal Year 2024

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for Its Proposed Rituximab Biosimilar

Dr. Reddy's Laboratories Limited to Report Q1, 2025 Results on Jul 27, 2024

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Dr. Reddy's Laboratories Limited Announces Management Changes

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.